HTB

Gilead Sciences announces fourth quarter and full year 2012 financial results

On 4 February 2013, Gilead announced details of its antiviral product sales which increased 17 percent to $2.17 billion for the fourth quarter of 2012, up from $1.86 billion for the fourth quarter of 2011.

This reflects sales growth of 20 percent in the U.S. and 9 percent in Europe.

For 2012, antiviral product sales increased 15 percent to $8.14 billion from $7.05 billion in 2011, reflecting sales growth of 21 percent in the U.S. and 6 percent in Europe.

Source: Gilead press release. Gilead Sciences announces fourth quarter and full year 2012 financial results. (4 February 2013).

http://www.gilead.com/press

http://investors.gilead.com/preview/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1781144&highlight=

Links to other websites are current at date of posting but not maintained.